The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ilyicheva T.N.

Novosibirsk State University;
Vector State Research Center of Virology and Biotechnology

Netesov S.V.

Novosibirsk State University

Gureyev V.N.

Vector State Research Center of Virology and Biotechnology

COVID-19, influenza, and other acute respiratory viral infections: etiology, immunopathogenesis, diagnosis, and treatment. Part 2. Other acute respiratory viral infections

Authors:

Ilyicheva T.N., Netesov S.V., Gureyev V.N.

More about the authors

Journal: Molecular Genetics, Microbiology and Virology. 2022;40(3): 3‑12

DOI: 10.17116/molgen2022400313

Read: 3184 times

Download PDF (RU)
Contact the author
Table of contents

COVID-19, INFLUENZA, AND OTHER ACUTE RESPIRATORY VIRAL INFECTIONS: ETIOLOGY, IMMUNOPATHOGENESIS, DIAGNOSIS, AND TREATMENT. PART 2. OTHER ACUTE RESPIRATORY VIRAL INFECTIONS
COVID-19, INFLUENZA, AND OTHER ACUTE RESPIRATORY VIRAL INFECTIONS: ETIOLOGY, IMMUNOPATHOGENESIS, DIAGNOSIS, AND TREATMENT. PART 2. OTHER ACUTE RESPIRATORY VIRAL INFECTIONS

To cite this article:

Ilyicheva TN, Netesov SV, Gureyev VN. COVID-19, influenza, and other acute respiratory viral infections: etiology, immunopathogenesis, diagnosis, and treatment. Part 2. Other acute respiratory viral infections. Molecular Genetics, Microbiology and Virology. 2022;40(3):3‑12. (In Russ.)
https://doi.org/10.17116/molgen2022400313

Подписка 2026 Молекулярная генетика, микробиология и вирусология (Molecular Genetics, Microbiology and Virology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cross-neutralizing acti­vity of a live intranasal vaccine based on the reco­mbinant Sendai virus of the Moscow strain against different variants of SARS-CoV-2. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(4):39-47
A rational approach to the prevention and treatment of ARVI and influenza, as a medico-economic and socially significant problem of the XXI century. Journal of Respiratory Medi­cine. 2025;(1):43-48
Post-Covid aortitis with cardiac invo­lvement: progressive aortic aneurysm combined with active myocarditis. Russian Journal of Archive of Pathology. 2025;(2):53-58
Post-exposure prophylaxis of influenza and ARVI. Resu­lts of a double-blind, placebo-controlled clinical trial of Meglumine acri­done acetate and its pharmacoeconomic rationale. Russian Journal of Preventive Medi­cine. 2025;(4):57-66
Therapeutic pote­ntial of quercetin and its deri­vatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50
Abstract:

The first part of this paper presented the current knowledge on two most significant respiratory diseases with high pandemic potential, COVID-19 and influenza. The second part reviews other pathogens that cause acute respiratory viral infections, ARVI, includingparainfluenza viruses, adenoviruses, pneumoviruses and specifically respiratory syncytial virus, enteroviruses, rhinoviruses,bocaviruses, and seasonal coronaviruses. The review presents modern data on the structure and replication of viruses, epidemiology and immunopathogenesis of diseases, diagnostics, preventive vaccination, and antiviral drugs. Topical issues regarding ARVI vaccination and the search for new broad-spectrum antiviral drugs are discussed.

Keywords:

ARVI
respiratory viruses
SARS-CoV-2
viral replication
immunopathogenesis
ARVI prophylaxis

Authors:

Ilyicheva T.N.

Novosibirsk State University;
Vector State Research Center of Virology and Biotechnology

Netesov S.V.

Novosibirsk State University

Gureyev V.N.

Vector State Research Center of Virology and Biotechnology

Received:

03.06.2021

Accepted:

30.10.2021

Close metadata

References:

  1. Chen N, Liu Y, Cheng Y, Liu L, Yan Z, Tao L, et al. Technology resource, distribution, and development characteristics of global influenza virus vaccine: A patent bibliometric analysis. PLoS One. 2015;10(9):e0136953. https://doi.org/10.1371/journal.pone.0136953
  2. Fricke R, Uibel S, Klingelhoefer D, Groneberg DA. Influenza: A scientometric and density-equalizing analysis. BMC Infectious Diseases. 2013;13(1):454.  https://doi.org/10.1186/1471-2334-13-454
  3. Gureyev VN, Mazov NA, Ilyicheva TN, Bazhan SI. An informetric analysis of studies on influenza vaccines and vaccination. OnLine Journal of Biological Sciences. 2017;17(4):372-381.  https://doi.org/10.3844/ojbsci.2017.372.381
  4. Haghani M, Bliemer MCJ, Goerlandt F, Li J. The scientific literature on Coronaviruses, COVID-19 and its associated safety-related research dimensions: A scientometric analysis and scoping review. Safety Science. 2020;129104806. https://doi.org/10.1016/j.ssci.2020.104806
  5. Lou J, Tian SJ, Niu SM, Kang XQ, Lian HX, Zhang LX, Zhang JJ. Coronavirus disease 2019: A bibliometric analysis and review. European Review for Medical and Pharmacological Sciences. 2020;24(6):3411-3421. https://doi.org/10.26355/eurrev_202003_20712
  6. Calderaro A, De Conto F, Buttrini M, Piccolo G, Montecchini S, Maccari C et al. Human respiratory viruses, including SARS-CoV-2, circulating in the winter season 2019—2020 in Parma, Northern Italy. International Journal of Infectious Diseases. 2021;10279-10284. https://doi.org/10.1016/j.ijid.2020.09.1473
  7. Galli C, Pellegrinelli L, Bubba L, Primache V, Anselmi G, Delbue S et al. When the covid-19 pandemic surges during influenza season: Lessons learnt from the sentinel laboratory-based surveillance of influenza-like illness in lombardy during the 2019—2020 season. Viruses. 2021;13(4). https://doi.org/10.3390/v13040695
  8. Ilyicheva TN, Gureyev VN. The impact of anti-epidemic measures against coronavirus disease 2019 (COVID-19) on the seasonal influenza epidemic. Chinese Medical Journal. 2021;134(7):879-880.  https://doi.org/10.1097/CM9.0000000000001344
  9. Groves HE, Piché-Renaud P, Peci A, Farrar DS, Buckrell S, Bancej C et al. The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada. medRxiv. 2021. https://doi.org/10.1101/2021.04.15.21255591
  10. Adlhoch C, Mook P, Lamb F, Ferland L, Melidou A, Amato-Gauci AJ et al. Very little influenza in the WHO European Region during the 2020/21 season, weeks40 2020 to 8 2021. Eurosurveillance. 2021;26(11):1-8.  https://doi.org/10.2807/1560-7917.ES.2021.26.11.2100221
  11. Baggen J, Thibaut HJ, Strating JRPM, Van Kuppeveld FJM. The life cycle of non-polio enteroviruses and how to target it. Nature Reviews Microbiology. 2018;16(6):368-381.  https://doi.org/10.1038/s41579-018-0005-4
  12. Xue YC, Feuer R, Cashman N, Luo H. Enteroviral infection: The forgotten link to amyotrophic lateral sclerosis? Frontiers in Molecular Neuroscience. 2018;1163. https://doi.org/10.3389/fnmol.2018.00063
  13. Lim HX, Poh CL. Insights into innate and adaptive immune responses in vaccine development against EV-A71. Therapeutic Advances in Vaccines and Immunotherapy. 2019;71-10.  https://doi.org/10.1177/2515135519888998
  14. Lewis-Rogers N, Seger J, Adler FR. Human rhinovirus diversity and evolution: How strange the change from major to minor. Journal of Virology. 2017;91(7):e01659-16.  https://doi.org/10.1128/JVI.01659-16
  15. Ledford RM, Patel NR, Demenczuk TM, Watanyar A, Herbertz T, Collett MS, Pevear DC. VP1 Sequencing of All Human Rhinovirus Serotypes: Insights into Genus Phylogeny and Susceptibility to Antiviral Capsid-Binding Compounds. Journal of Virology. 2004;78(7):3663-3674. https://doi.org/10.1128/JVI.78.7.3663-3674.2004
  16. Jacobs SE, Lamson DM, Kirsten S, Walsh TJ. Human rhinoviruses. Clinical Microbiology Reviews. 2013;26(1):135-162.  https://doi.org/10.1128/CMR.00077-12
  17. Mäkelä MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimäki M, et al. Viruses and bacteria in the etiology of the common cold. Journal of Clinical Microbiology. 1998;36(2):539-542.  https://doi.org/10.1128/jcm.36.2.539-542.1998
  18. Turner RB. Epidemiology, pathogenesis, and treatment of the common cold. Annals of Allergy, Asthma and Immunology. 1997;78(6):531-540.  https://doi.org/10.1016/S1081-1206(10)63213-9
  19. Jartti T, Gern JE. Rhinovirus-associated wheeze during infancy and asthma development. Current Respiratory Medicine Reviews. 2011;7(3):160-166.  https://doi.org/10.2174/157339811795589423
  20. Henrickson KJ. Parainfluenza viruses. Clinical Microbiology Reviews. 2003;16(2):242-264.  https://doi.org/10.1128/CMR.16.2.242-264.2003
  21. Weston S, Frieman MB. Respiratory viruses. InEncyclopedia of Microbiology. 2019;85-101. 
  22. Lamb RA, Parks GD. Paramyxoviridae: The Viruses and Their Replication. InFields virology: Sixth edition. Philadelphia: Wolters Kluwer/Lippincott, Williams, and Wilkins. 2013;957-995. 
  23. Alayyoubi M, Leser GP, Kors CA, Lamb RA. Structure of the paramyxovirus parainfluenza virus 5 nucleoprotein-RNA complex. Proceedings of the National Academy of Sciences of the United States of America. 2015;112(14):1792-1799. https://doi.org/10.1073/pnas.1503941112
  24. Russell CJ, Simões EAF, Hurwitz JL. Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles. Viral Immunology. 2018;31(2):133-141.  https://doi.org/10.1089/vim.2017.0137
  25. Amarasinghe GK, Bào Y, Basler CF, Bavari S, Beer M, Bejerman N et al. Taxonomy of the order Mononegavirales: update 2017. Archives of Virology. 2017;162(8):2493-2504. https://doi.org/10.1007/s00705-017-3311-7
  26. Mammas IN, Spandidos DA. Updating taxonomy changes: RSV is now known as Orthopneumovirus. International Journal of Molecular Medicine. 2019;44(S312019).
  27. Li Y, Reeves RM, Wang X, Bassat Q, Brooks WA, Cohen C, et al. Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. The Lancet Global Health. 2019;7(8):1031-1045. https://doi.org/10.1016/S2214-109X(19)30264-5
  28. Ascough S, Paterson S, Chiu C. Induction and subversion of human protective immunity: Contrasting influenza and respiratory syncytial virus. Frontiers in Immunology. 2018;9323. https://doi.org/10.3389/fimmu.2018.00323
  29. Johnson SM, McNally BA, Ioannidis I, Flano E, Teng MN, Oomens AG et al. Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures. PLoS Pathogens. 2015;11(12):e1005318. https://doi.org/10.1371/journal.ppat.1005318
  30. Americanassociationforrespiratorycare. Aerosol consensus statement — 1991. Respiratory Care. 1991;36(9):916-921. 
  31. Krivitskaya VZ. Respiratory syncytial virus infection. pathogenesis peculiarities, prevention and treatment strategies. Voprosy sovremennoj pediatrii. 2013;12(2):35-43. (In Russ.).
  32. Wang D, Cummins C, Bayliss S, Sandercock J, Burls A. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: A systematic review and economic evaluation. Health Technology Assessment. 2008;12(36). https://doi.org/10.3310/hta12360
  33. RSV Clinical Trial Tracker. 2020. Accessed April 20, 2021. https://www.path.org/resources/rsv-and-mab-trial-tracker.
  34. Van Den Hoogen BG, De Jong JC, Groen J, Kuiken T, De Groot R, Fouchier RAM, Osterhaus ADME. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nature Medicine. 2001;7(6):719-724.  https://doi.org/10.1038/89098
  35. Human Metapneumovirus (HMPV) Clinical Features. 2021. Accessed April 20, 2021. https://www.cdc.gov/surveillance/nrevss/hmpv/clinical.html.
  36. Hamelin MÈ, Abed Y, Boivin G. Human metapneumovirus: A new player among respiratory viruses. Clinical Infectious Diseases. 2004;38(7):983-990.  https://doi.org/10.1086/382536
  37. Bao X, Liu T, Shan Y, Li K, Garofalo RP, Casola A. Human metapneumovirus glycoprotein G inhibits innate immune responses. PLoS Pathogens. 2008;4(5):e1000077. https://doi.org/10.1371/journal.ppat.1000077
  38. Kumar P, Srivastava M. Prophylactic and therapeutic approaches for human metapneumovirus. Virus Disease. 2018;29(4):434-444.  https://doi.org/10.1007/s13337-018-0498-5
  39. Hashimoto S, Gonzalez G, Harada S, Oosako H, Hanaoka N, Hinokuma R, Fujimoto T. Recombinant type Human mastadenovirus D85 associated with epidemic keratoconjunctivitis since 2015 in Japan. Journal of Medical Virology. 2018;90(5):881-889.  https://doi.org/10.1002/jmv.25041
  40. Ghebremedhin B. Human adenovirus: Viral pathogen with increasing importance. European Journal of Microbiology and Immunology. 2014;4(1):26-33.  https://doi.org/10.1556/eujmi.4.2014.1.2
  41. Lion T. Adenovirus infections in immunocompetent and immunocompromised patients. Clinical Microbiology Reviews. 2014;27(3):441-462.  https://doi.org/10.1128/CMR.00116-13
  42. Crenshaw BJ, Jones LB, Bell CR, Kumar S, Matthews QL. Perspective on Adenoviruses: Epidemiology, Pathogenicity, and Gene Therapy. Biomedicines. 2019;7(61):1-18.  https://doi.org/10.3390/biomedicines7030061
  43. Choudhry A, Mathena J, Albano JD, Yacovone M, Collins L. Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits. Vaccine. 2016;34(38):4558-4564. https://doi.org/10.1016/j.vaccine.2016.07.033
  44. Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(36):12891-12896. https://doi.org/10.1073/pnas.0504666102
  45. ICTV Taxonomy. 2021. Accessed April 20, 2021. https://talk.ictvonline.org/taxonomy
  46. Guido M, Tumolo MR, Verri T, Romano A, Serio F, De Giorgi M, et al. Human bocavirus: Current knowledge and future challenges. World Journal of Gastroenterology. 2016;22(39):8684-8697. https://doi.org/10.3748/wjg.v22.i39.8684
  47. Hamza H, Leifels M, Wilhelm M, Hamza IA. Relative Abundance of Human Bocaviruses in Urban Sewage in Greater Cairo, Egypt. Food and Environmental Virology. 2017;9(3):304-313.  https://doi.org/10.1007/s12560-017-9287-3
  48. Fehr AR, Perlman S. Coronaviruses: An overview of their replication and pathogenesis. In Methods in Molecular Biology. 2015;1282. https://doi.org/10.1007/978-1-4939-2438-7_1
  49. Forni D, Cagliani R, Clerici M, Sironi M. Molecular Evolution of Human Coronavirus Genomes. Trends in Microbiology. 2017;25(1):35-48.  https://doi.org/10.1016/j.tim.2016.09.001
  50. Huynh J, Li S, Yount B, Smith A, Sturges L, Olsen JC et al. Evidence supporting a Zoonotic Origin of human coronavirus strain NL63. Journal of Virology. 2012;86(23):12816-12825. https://doi.org/10.1128/JVI.00906-12
  51. Pfefferle S, Oppong S, Drexler JF, Gloza-Rausch F, Ipsen A, Seebens A et al. Distant relatives of severe acute respiratory syndrome coronavirus and close relatives of human coronavirus 229E in bats, Ghana. Emerging Infectious Diseases. 2009;15(9):1377-1384. https://doi.org/10.3201/eid1509.090224
  52. Zhang Z, Shen L, Gu X. Evolutionary Dynamics of MERS-CoV: Potential Recombination, Positive Selection and Transmission. Scientific reports. 2016;625049. https://doi.org/10.1038/srep25049
  53. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594-599.  https://doi.org/10.1038/s41586-020-2814-7
  54. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. 2020:396(10249);467-478.  https://doi.org/10.1016/S0140-6736(20)31604-4
  55. Cheryl K, Gregory MG, Gary A, Iksung C, Andreana R, Patricia Ret al. First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. medRxiv. 2020. https://doi.org/10.1101/2020.08.05.20168435
  56. Parks JM, Smith JC. How to discover antiviral drugs quickly. New England Journal of Medicine. 2020;382(23):2261-2264. https://doi.org/10.1056/NEJMcibr2007042
  57. Amaro RE, Baudry J, Chodera J, Demir Ö, McCammon JA, Miao Y, Smith JC. Ensemble Docking in Drug Discovery. Biophysical Journal. 2018;114(10):2271-2278. https://doi.org/10.1016/j.bpj.2018.02.038
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.